Insilico Medicine reported a profitability turnaround forecast for the first half of 2026, driven by its AI-enabled pipeline progress and partner-driven revenue. In StockWatch coverage, the company projected net profit of roughly $33.5 million to $39.5 million for H1 2026 versus a net loss in the prior-year period. Insilico also forecast record first-half revenue in the range of about $102.5 million to $106.5 million, up roughly 273% to 287% year over year. The company attributed the improvement to collaborations plus the timing of pipeline milestones, with the first program described as having moved into late-stage development. The update is notable for investors because it pairs top-line momentum with cash strengthening, including a reported more-than-tripling of cash and cash equivalents to $393.3 million. The company said it aims for sustained profitability, underscoring a shift from burn-driven execution toward milestone and commercialization readiness. For biotech market watchers, Insilico’s read-through is that AI drug discovery is increasingly evaluated on late-stage readiness and partnership economics—not just discovery claims.